Skin Tightening · Ultrasound Mapping · A Physician's Perspective
The Skin-Tightening Debate Is Asking the Wrong Question
It is not which device is best. It is which tissue you are trying to treat.
The short answer
Sofwave's approval in mainland China has made one question especially relevant: if a clinic already owns Thermage and Ultherapy, does adding Sofwave make clinical and business sense?
My answer is yes — for the right patient. But I no longer think the useful question is which device is best. I think the better question is: how thick is the tissue I am actually trying to treat?
When ultrasound shows a predominantly superficial dermal target around 1–2 mm, Sofwave's 1.5 mm-centred treatment geometry makes a great deal of sense. When the dermis or collagen-rich superficial soft-tissue envelope extends into the 3–4 mm range or deeper, I become more interested in bulk heating with monopolar RF such as Thermage or XERF.
Ultherapy remains the most versatile because it lets me see the anatomy in real time and choose 1.5, 3.0 or 4.5 mm treatment depths. In many patients I would rather combine a broad tightening treatment with 100–200 customized Ultherapy lines for specific deeper targets than force one technology to do everything.
The principle is simple: do not choose by ethnicity. Measure the anatomy.
Why I am revisiting this now
When I first wrote my comparison of Ultherapy, Thermage and Sofwave, my conclusion was that none of them is universally best. I still believe that.
My emphasis on tissue thickness is not new. I have taught for years that melanin, hemoglobin and tissue thickness are three core variables that should shape energy-based treatment planning through my DALASS framework. Sofwave's arrival in China does not change that thinking; it simply gives me another technology to place within it.
What makes Sofwave interesting in this context is that its approximately 1.5 mm-centred treatment geometry is very different from bulk monopolar RF or multi-depth Ultherapy. That makes the thickness question especially relevant when deciding where Sofwave fits in a clinic that already owns Thermage and Ultherapy.
Then Sofwave received NMPA approval in mainland China in September 2026. The approval covers improvement of wrinkles in the mid-to-lower face for individuals aged 22 and older. According to the company, it was supported by a prospective, randomized, blank-controlled superiority study of 200 subjects aged 22 to 65 across five Chinese sites, reporting 95.1% improvement on the Global Aesthetic Improvement Scale against 23.4% in controls.
Since then, a number of doctors in China have asked me whether they should add Sofwave.
The context in China is unusual because many established aesthetic clinics already have both Thermage and Ultherapy. So the question is not whether Sofwave can replace either one. The more interesting question is whether it fills a clinical gap.
I think it can — if we stop organizing patients by device and start organizing them by anatomy.
The argument Sofwave gets right
Sofwave is deliberately a relatively superficial treatment. Its SUPERB ultrasound technology is designed to create a thermal effect between roughly 0.5 and 2 mm, centered at about 1.5 mm in the mid-dermis.
That is not a weakness if the target tissue is actually there.
And in many patients, it is.
High-frequency ultrasound studies repeatedly show that facial skin thickness varies substantially by location and by patient. Published measurements often place facial dermis in the 1–2 mm range, particularly in thinner facial regions. A 2026 ultrasound review of cheek anatomy, for example, describes dermal thickness across cheek subunits from roughly 0.6 to 2.1 mm.
That is why I understand the Sofwave argument better now than I did when I first looked at the technology. If the meaningful treatment target is 1–2 mm deep, placing the thermal injury at 1.5 mm is efficient.
You do not get extra credit for heating tissue you did not need to treat.
But not everybody has a 1–2 mm target
This is where my own experience with Ultherapy keeps me from accepting a universal 1.5 mm model.
After nearly two decades of treating with ultrasound, I have seen enormous anatomical variation. Many patients are thin. Many are not.
Published ultrasound data support that variability. One recent review summarizes facial dermal thickness as roughly 1.0 to 4.0 mm depending on location, with thicker facial regions reported around 3–4 mm. Histology-correlated high-frequency ultrasound has measured upper-lip dermis around 3.4–3.7 mm in some cohorts. Other facial ultrasound work has documented cheek dermis up to about 3.3 mm.
In clinical imaging, I also encounter patients where the collagen-rich superficial envelope I care about extends even deeper. At 4–6 mm, I become careful with terminology because we are often no longer talking about pure dermis alone; we may be looking at deep dermis, fibroseptal tissue, superficial fat and the fibromuscular plane together.
But clinically, that distinction actually strengthens the point:
The treatment target is not the same depth in every face.
Do not treat the ethnicity. Treat the anatomy.
This is also why I do not think thickness should be treated as a new standalone idea. In DALASS, I already look at melanin, hemoglobin and tissue thickness before deciding how aggressive an energy-based treatment should be. Thickness has always been one of the three variables.
I have heard the argument that Asian patients have a “stronger cellular matrix” and therefore respond differently to tightening technologies.
There may be population-level differences in collagen architecture, facial fat distribution and aging pattern. But those averages are not precise enough to prescribe an individual treatment.
I can find a Caucasian patient with thick tissue and an Asian patient with very thin tissue on the same afternoon.
If I have an ultrasound probe in my hand, why would I guess?
High-frequency ultrasound can visualize the skin from the surface down to deep fascia in real time. The dermis itself is distinguishable because its collagen-rich structure produces a characteristic echogenic pattern, and deeper subcutaneous and fascial layers can also be mapped.
The practical change
I think we should use ultrasound more often during the initial tightening consultation — not just during Ultherapy treatment.
Measure the patient first. Then decide which energy geometry makes sense.
A thickness-based way to think about the devices
This is not a validated treatment algorithm. It is the clinical framework I am increasingly using to think about patient selection.
| What ultrasound shows | Technology I would consider first | Why |
|---|---|---|
| Predominantly superficial dermal target around 1–2 mm | Sofwave | Its thermal effect is centered at about 1.5 mm; efficient match to a superficial dermal target. |
| Thicker dermis / collagen-rich superficial envelope around 3–4 mm | Thermage or XERF | Broad monopolar RF bulk heating may make more sense when the treatment volume extends beyond a narrow 1.5 mm band. |
| Specific deeper target at 3.0 or 4.5 mm | Ultherapy | Real-time visualization plus selectable focal depths makes it ideal for anatomy-specific treatment. |
| Mixed superficial + focal deep laxity | Sofwave or Thermage/XERF + Ultherapy | Use one technology for broad tissue remodeling and a customized number of Ultherapy lines for the deeper problem areas. |
This table describes my current clinical reasoning, not a validated comparative protocol. Exact depth, dose and treatment choice still depend on anatomy, indication, device characteristics and operator judgement.
The flow chart
Where Sofwave fits in a clinic that already has Thermage and Ultherapy
If a Chinese clinic already owns Thermage and Ultherapy, I do not see Sofwave as redundant.
I see a potential workflow advantage.
For a patient whose problem is mainly a thin, superficial dermal laxity pattern, Sofwave may give the clinic a faster and simpler way to treat the tissue that actually needs treatment. A treatment does not become better because it takes longer.
That matters commercially as well as clinically. If Sofwave can treat an appropriate superficial candidate efficiently, it can improve treatment-room throughput without asking the clinic to abandon the technologies it already owns.
The business argument only works, however, if the clinic can identify that patient reliably. Otherwise Sofwave becomes just another expensive device being used on everybody.
Where XERF or Thermage still makes more sense to me
When ultrasound shows a thicker tissue envelope, I become more interested in monopolar RF.
Unlike a focal ultrasound treatment, monopolar RF produces a broad three-dimensional thermal field. With XERF, the published modelling also shows that frequency changes where heating is concentrated: 6.78 MHz favors heating along fibrous septa, while 2 MHz produces broader, deeper bulk heating through adipose tissue.
That does not prove that a 3–4 mm patient will always respond better to XERF than to Sofwave. Nobody has done that study.
But it is a testable anatomical hypothesis: when the collagen-rich treatment volume is thicker, a bulk-heating strategy may be a better geometric match than a narrow mid-dermal treatment band.
Ultherapy is still the most versatile tool
If I could keep only one tightening technology from the standpoint of anatomical versatility, Ultherapy would still be very difficult to replace.
It can deliver focal thermal coagulation at 1.5, 3.0 and 4.5 mm, and the real-time ultrasound image lets the operator see where those depths sit in that particular patient before firing.
That does not mean every patient needs a traditional full-face Ultherapy treatment.
In fact, owning several technologies makes me more interested in using Ultherapy selectively.
A patient might receive Sofwave for a superficial dermal problem and then 100–200 Ultherapy lines to a deeper submental or jawline target. Another might receive XERF for broader dermal and subdermal remodeling, followed by a customized set of 4.5 mm Ultherapy lines where I want focal structural treatment.
Ultherapy does not have to compete with broad heating. It can become the precision layer on top of it.
The exact line count is my clinical choice rather than a validated universal protocol. The principle is simply to stop using a full treatment template when only selected deeper areas need additional treatment.
Why ultrasound should move into the consultation room
This may be the most important part of the entire idea.
We already accept imaging when we need precision in other parts of medicine. Yet aesthetic tightening is still often prescribed by looking at a face, estimating age and skin type, and choosing a device from experience.
Experience matters. But measurement is better when measurement is available.
High-frequency ultrasound can show dermal thickness, subcutaneous thickness, fibrous septa and fascial structures. Echogenicity can also provide information about tissue organization, although I would not pretend it is a direct quantitative collagen assay.
The goal is not to turn every aesthetic consultation into radiology.
The goal is to answer a simple question before spending thousands of dollars on treatment:
Where is the tissue I actually want to change?
This is not a 1.5 mm versus 4.5 mm war
One thing I have become increasingly skeptical of is manufacturer education that tries to turn one engineering decision into a universal biological truth.
Sofwave is right that a lot of clinically useful dermal tissue sits around 1–2 mm.
Ultherapy is right that patients vary substantially and that deeper 3.0 and 4.5 mm targets matter in selected anatomy.
Monopolar RF is right for a different reason: sometimes what I want is not a row of focal coagulation points at one exact depth. Sometimes I want a broader volume of thermal remodeling.
All three statements can be true at the same time.
That is why I no longer find the question “Which technology is best?” very interesting.
The more interesting question is:
Which energy geometry best matches this patient's tissue geometry?
The study I would like to see
This framework is still a hypothesis. It needs to be tested.
The first study I would run is actually simpler than a Sofwave-versus-XERF-versus-Ultherapy trial.
I would take one device — XERF is an obvious candidate — and prospectively categorize patients by pretreatment ultrasound measurements.
| Study element | Proposed approach |
|---|---|
| Baseline imaging | Standardized ultrasound measurements at fixed facial landmarks: dermis, superficial fat and depth to relevant fascial plane. |
| Thickness strata | For example: ≤2 mm, 2–3 mm, 3–4 mm and >4 mm for the predefined target tissue measurement. |
| Treatment | One standardized XERF protocol, with technique and delivered energy recorded rather than changed retrospectively to fit the result. |
| Outcomes | Blinded photography, 3D stereophotogrammetry, FACE-Q, objective laxity scoring and repeat ultrasound at defined follow-up points. |
| Main question | Does baseline tissue thickness predict magnitude, speed or pattern of clinical response? |
A more ambitious second study could randomize patients within thickness strata to Sofwave, monopolar RF and MFU-V. The important methodological change would be stratifying by anatomy before comparing devices.
If thickness turns out not to predict response, then this framework should be revised.
If it does predict response, then we may finally have a more useful way to talk about tightening than brand versus brand.
If you are an energy-device nerd...
There is also a less academic answer to the business question.
If you are an energy-based device nerd, you genuinely enjoy learning new technologies, and the budget allows it, owning all of them is actually pretty amazing.
From a business perspective, that can look irrational at first. Sofwave, Thermage, XERF and Ultherapy all seem to overlap. They are all marketed for some version of tightening, lifting, collagen stimulation and non-surgical rejuvenation. On a spreadsheet, it is easy to ask why a clinic would need more than one.
But in daily practice, the overlap is not complete.
Sofwave gives me a fast, superficial mid-dermal option. Thermage and XERF give me broad monopolar RF heating with a different tissue interaction and treatment geometry. Ultherapy gives me real-time visualization and the ability to place focal energy at specific depths.
Once you stop asking which device should win, the redundancy starts to look more like a toolbox.
The technologies overlap in indication, but not completely in anatomy.
That may not justify buying everything on day one. But for a mature practice with enough patient volume, enough clinical curiosity and enough budget, I can absolutely see the value of having all of them available and choosing the tool according to the tissue in front of me.
The bottom line
Sofwave's arrival in China should not be framed as the next device replacing Thermage or Ultherapy.
For clinics that already own both, it may make sense precisely because it is different.
A superficial 1–2 mm target may be an excellent Sofwave case.
A thicker 3–4 mm dermal or superficial soft-tissue target may make me lean toward Thermage or XERF.
A focal deep target at 3.0 or 4.5 mm may be where Ultherapy adds the most value.
And many patients will need more than one of those answers.
It is not either-or.
What I want to move away from is prescribing technology based on ethnicity, age brackets or whichever machine happens to be sitting in the room.
I would rather measure the anatomy first.
And if the clinic is fortunate enough to have several good technologies available, that is not necessarily redundancy. It can be an advantage — as long as each machine has a defined anatomical role instead of being forced onto every patient.
Do not choose the device and then fit the patient into it. Map the patient, then choose the device.
Sources
Company announcement of NMPA approval for mid-to-lower facial wrinkle improvement in adults 22 and older; states that approval was supported by a 200-subject randomized controlled study in China.
Manufacturer source describing the treatment effect as centered at 1.5 mm in the mid-dermis. Sofwave product literature further describes a thermal zone approximately 0.5–2 mm deep.
Manufacturer source describing 1.5, 3.0 and 4.5 mm focal treatment depths and emphasizing patient-to-patient variation in tissue layer thickness and distribution.
Review supporting the use of HFUS for real-time imaging from skin surface to deep fascia, including measurement of skin thickness and visualization of collagen-rich dermal structures.
Recent review summarizing facial dermal thickness as approximately 1.0–4.0 mm depending on location, with thicker regions such as cheek and forehead reaching about 3–4 mm.
Histology-correlated facial ultrasound study reporting cheek dermis around 2.0 mm and upper-lip dermis around 3.4–3.7 mm in the study cohorts.
Facial ultrasound measurements showing wide inter-individual variation; cheek dermis ranged up to about 3.3 mm and subcutaneous thickness varied by several millimetres.
Source for the frequency-dependent XERF heat distribution discussed here: more septal concentration at 6.78 MHz and broader, deeper adipose heating at 2 MHz.
Accurate as of October 2026. Device indications and published evidence continue to evolve.